- Investing.com
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Metrics to compare | ZURA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZURAPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.9x | −4.9x | −0.6x | |
PEG Ratio | 0.10 | 0.02 | 0.00 | |
Price/Book | 2.0x | 2.4x | 2.6x | |
Price / LTM Sales | - | 10.2x | 3.4x | |
Upside (Analyst Target) | 230.8% | 122.9% | 35.5% | |
Fair Value Upside | Unlock | −2.8% | 3.7% | Unlock |